00:16:27 · Sebastian Johnson, Neil Daly
[00:16:27] S0: Amazing. And, like, I think it's such a phenomenal job that you're doing and and an amazing mission. I think one final question. Right? You raised a series b last year. You've had these amazing milestones since you raised that round. What's next? You know, like, what's next on the immediate priority list? Like, what what takes you from where you are today to that next stage of your journey? [00:16:47] S1: Yeah. I think that the secret for us right now is is to make sure that all of these really exciting opportunities that we're talking to care providers across Europe, deployed. And we show that across a number of different models, our technology can really support those outcomes rather than just being focused in The UK. We're able to show that it works across Europe. And, of course, The US is a a huge focus for us, and so, translating that technology, making sure that we are able to unlock value in The US for the health care system, that is a very different problem. I think that we all know that The US approaches health care in a very different way to the way that we do across Europe. So those are two big things for us to focus on right now, and I think that, you know, we're growing really, really well at the moment. We're able to to really sign on more and more partners. We're just about to announce something in the in the coming weeks and months that, that, is pretty exciting, and then we'll continue to build on that, build on that, build on that across Europe, and eventually, we hope to be the number one way to solve skin cancer across the globe.
00:16:47 · Neil Daly, Sebastian Johnson
[00:16:47] S1: Yeah. I think that the secret for us right now is is to make sure that all of these really exciting opportunities that we're talking to care providers across Europe, deployed. And we show that across a number of different models, our technology can really support those outcomes rather than just being focused in The UK. We're able to show that it works across Europe. And, of course, The US is a a huge focus for us, and so, translating that technology, making sure that we are able to unlock value in The US for the health care system, that is a very different problem. I think that we all know that The US approaches health care in a very different way to the way that we do across Europe. So those are two big things for us to focus on right now, and I think that, you know, we're growing really, really well at the moment. We're able to to really sign on more and more partners. We're just about to announce something in the in the coming weeks and months that, that, is pretty exciting, and then we'll continue to build on that, build on that, build on that across Europe, and eventually, we hope to be the number one way to solve skin cancer across the globe. [00:17:49] S0: I love it. Well look Neil, thank you so much for taking the time, think it's really cool what you're doing and I look forward to following on your journey and seeing you continue to go from strength to strength. [00:17:58] S1: Thanks very much, Seth, really appreciate the chance to to chat to you and share a little bit more about what we're up to.